Form 4: RA Capital Boosts Stake in Aerovate Therapeutics with $1.55 Million Purchase

RA Capital Management and related entities increased their holdings in Aerovate Therapeutics, acquiring 928,110 shares at an average price of $1.67.

Summary

• RA Capital Management, L.P., along with related funds and individuals, reported changes in their beneficial ownership of Aerovate Therapeutics, Inc. common stock.
• On June 17, 2024, RA Capital Healthcare Fund, L.P. purchased 928,110 shares of Aerovate Therapeutics at a weighted average price of $1.67, with prices ranging from $1.51 to $1.75.
• Following the transaction, RA Capital Healthcare Fund, L.P. directly holds 7,893,678 shares.
• RA Capital Nexus Fund, L.P. directly holds 987,244 shares, and a separately managed account holds 311,170 shares.
• RA Capital Management, L.P., as the investment manager for these entities, along with its general partner RA Capital Management GP, LLC, and managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah, disclaim beneficial ownership except to the extent of their pecuniary interest.
• Mr. Joshua Resnick, a Senior Managing Director of RA Capital Management, L.P., serves on Aerovate Therapeutics' board of directors.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. RA Capital increasing its stake suggests confidence, but it's a routine transaction disclosure.

Positives

• RA Capital's increased investment could be seen as a positive signal for Aerovate Therapeutics, indicating confidence in the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or significant shareholders of a publicly traded company buy or sell shares. This filing indicates changes in ownership by a major shareholder, RA Capital, which is relevant to investors monitoring the stock.

Comparison to Industry Standards

• Form 4 filings are a standard part of regulatory compliance for major shareholders in publicly traded companies.
• The disclosed information allows investors to track insider activity, which can be compared to similar filings for other companies in the biotechnology sector to gauge investor sentiment and confidence.

Stakeholder Impact

• The increased stake by RA Capital could positively influence shareholder confidence.
• The transaction itself has no direct impact on employees, customers, suppliers, or creditors.

Key Dates